These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 15661422)
1. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines. Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422 [TBL] [Abstract][Full Text] [Related]
2. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill. Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659 [TBL] [Abstract][Full Text] [Related]
3. A gene therapy/targeted radiotherapy strategy for radiation cell kill by. Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115 [TBL] [Abstract][Full Text] [Related]
4. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352 [TBL] [Abstract][Full Text] [Related]
5. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875 [TBL] [Abstract][Full Text] [Related]
6. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. Mairs RJ; Ross SC; McCluskey AG; Boyd M J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246 [TBL] [Abstract][Full Text] [Related]
7. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418 [TBL] [Abstract][Full Text] [Related]
8. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. Boyd M; Mairs SC; Stevenson K; Livingstone A; Clark AM; Ross SC; Mairs RJ J Gene Med; 2002; 4(5):567-76. PubMed ID: 12221650 [TBL] [Abstract][Full Text] [Related]
10. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344 [TBL] [Abstract][Full Text] [Related]
11. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311 [TBL] [Abstract][Full Text] [Related]
12. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418 [TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636 [TBL] [Abstract][Full Text] [Related]
14. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120 [TBL] [Abstract][Full Text] [Related]
15. Gene manipulation to enhance MIBG-targeted radionuclide therapy. Mairs RJ; Fullerton NE; Cosimo E; Boyd M Nucl Med Biol; 2005 Oct; 32(7):749-53. PubMed ID: 16243651 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes. Weber W; Weber J; Senekowitsch-Schmidtke R Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097 [TBL] [Abstract][Full Text] [Related]
17. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy. Mitrofanova E; Unfer R; Vahanian N; Link C Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480 [TBL] [Abstract][Full Text] [Related]
18. Expression of a recombinant vector of a mutant human telomerase reverse transcriptase gene in human bladder cancer cell line T24, and its clinical significance. Fu WJ; Hong BF; Huang JJ; Xu B; Gao JP; Wang XX; Huang CF BJU Int; 2005 Oct; 96(6):890-4. PubMed ID: 16153224 [TBL] [Abstract][Full Text] [Related]
19. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Kölby L; Bernhardt P; Johanson V; Wängberg B; Muth A; Jansson S; Forssell-Aronsson E; Nilsson O; Ahlman H Ann N Y Acad Sci; 2006 Aug; 1073():491-7. PubMed ID: 17102116 [TBL] [Abstract][Full Text] [Related]
20. Nuclear medicine therapy of neuroblastoma. Hoefnagel CA Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]